Looking through news archives, Goldshield was sold/bought out in 2009, and I started having issues with Eltroxin 25mcg in 2012 - that would have been manufactured in 2010. The following year the 50mcg strength changed. Strangely the 100 mcg strength was fine until Eltroxin was discontinued. Before these changes/problems I had taken Eltroxin (25 & 50 mcg) for 14 years with no problems.
Until recently I found the 100 mcg MP levo was much better than the 25/50 mcg MP levo. I have just started a new batch of 100 mcg MP levo and am having awful allergy problems with it, which is what was I experienced with the 25/50 mcg MP levo. My suspicion has always been that changes have been gradually made to reduce costs, and they are now using an inferior form of thyroxine. There have been further changes to the management/ownership of MP/Amco since 2009 I understand.
The people who own(ed) MP have been implicated in the price fixing of generics this summer, which gives an idea how much they care about patients. It would appear to be all about profit.
E.g. The price of liothyronine (also made by MP/Amco) has gone from 67p per tablet to £9.22 per tablet (it is now costing me £200.00 a month for T3 on a private script).
Another thing to consider is that the is tolerances within the specification of the product licence are quite wide. I contacted the MHRA about this. Apparently the tolerance for the active ingredient in levothyroxine sodium, can vary by up to 25% (between 85% to 110%) and still be within the tolerances of what is acceptable.
Let's hope we can find a solution somehow.